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Abstract
Background: Clinical research indicates that periconceptional administration of folic acid can reduce the occurrence of
congenital cardiac septal defects (CCSDs). The vital roles of folate exhibits in three ways: the unique methyl donor for DNA
expression regulation, the de novo biosynthesis of purine and pyrimidine for DNA construction, and the serum homocysteine
removal. Thymidylate synthase (TYMS) is the solo catalysis enzyme for the de novo synthesis of dTMP, which is the essential
precursor of DNA biosynthesis and repair process. To examine the role of TYMS in Congenital Cardiac Septal Defects (CCSDs)
risk,weinvestigatedwhether geneticpolymorphismsin theTYMSgene associatedwiththeCCSDsinaHan Chinesepopulation.
Method: Polymorphisms in the noncoding region of TYMS were identified via direct sequencing in 32 unrelated individuals
composed of half CCSDs and half control subjects. Nine SNPs and two insertion/deletion polymorphisms were genotyped
from two independent case-control studies involving a total of 529 CCSDs patients and 876 healthy control participants. The
associations were examined by both single polymorphism and haplotype tests using logistic regression.
Result: We found that TYMS polymorphisms were not related to the altered CCSDs risk, and even to the changed risk of
VSDs subgroup, when tested in both studied groups separately or in combination. In the haplotype analysis, there were no
haplotypes significantly associated with risks for CCSDs either.
Conclusion: Our results show no association between common genetic polymorphisms of the regulatory region of the
TYMS gene and CCSDs in the Han Chinese population.
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Introduction
Congenital heart disease is one of the most common birth defects
and among the leading causes of infant death worldwide, with an
incidence of 19 to 75 per 1,000 live births [1]. Clinical research over
the past twenty years suggests that maternal periconceptional folic
acid supplementation would reduce the occurrence of congenital
heart disease by 40–60%, especially for congenital cardiac septal
defects (CCSDs) and conotruncal defects [2–9]. Moreover, folate
antagonists increase congenital heart disease risk, particularly
CCSDs and conotruncal malformations [10].
Folate acts as a one-carbon donor, which is involved in both the
de novo synthesis of nucleotides and methyl transfer reactions.
Therefore exploring the association between genetic variants in
genes involved in folate metabolism pathway and the risk of
CCSD will shed light on the mechanism how folate carries out its
protection effects. Considering the interacted environmental
factors, it was speculated that fetuses with the genetic susceptibility
will be more fragile when challenged by the maternal absence of
folate, especially during the embryonic heart development period
[11–13]. So folate supplement should be supplemented during the
first trimester of pregnancy.
Thymidylate synthase (TYMS) is the key enzyme in the de novo
synthesis of 29-deoxyuridine -59-monophosphate (dTMP), which is
the essential precursor of DNA biosynthesis and repair process
[14]. Numerous studies have shown that the polymorphisms in
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31644TYMS gene influence the enzyme’s activity and correlate with the
folate levels [15–18]. The most extensively reported TYMS
variants are two insertion/deletion sites in 59UTR (rs34743033)
and 39UTR (rs34489327), respectively, which are associated with
the occurrence of various tumors, such as colorectal cancer,
lymphoma, and acute lymphocytic leukemia [16,19,20].
Although the TYMS plays an important role in the developing
fetus and is closely related to many diseases, so far it has not yet
been reported to be associated with CCSDs in Han Chinese
population. In this study, we investigated the effects of two
extensively studied TYMS insertion/deletion sites on CCSDs,
including ventricular septal defects (VSDs), atrial septal defects
(ASDs) and complex traits composed of VSD and ASD, in a Han
Chinese population. Moreover, we extended this association study
to additional 9 common SNP sites (MAF.0.1) by sequencing and
analyzing the promoter, 59UTR and 39UTR regulatory regions of
TYMS.
Materials and Methods
Study subjects
We analyzed samples from two independent case-control
groups. The Shanghai group consisted of 270 CCSDs patients
and 552 matched healthy controls. These patients and controls
were enrolled between August 2008 and February 2011 from the
Children’s Hospital of Fudan University (Shanghai, China). The
Shandong group consisted of 259 CCSDs patients and 324 healthy
controls. These patients and controls were recruited between
August 2008 and January 2011 from the Cardiovascular Disease
Institute, General Hospital of Jinan Military Command (Jinan,
Shandong Province, China). Among the 529 CCSDs patients, 447
had VSD, 31 ASD, 37 complex traits composed of VSD and ASD
and 14 other complex traits involved VSD. All of the controls were
non-CCSDs out-patients from the same geographic area who were
matched to affected individuals by age and sex during the same
period (Table 1). All subjects were genetically unrelated ethnic
Han Chinese. CCSDs patients who had structural malformations
involving another organ system or positive family history of
CCSDs in first-degree relatives (parents, siblings and children)
were excluded.
To screen non-coding variants in the TYMS gene, 32 unrelated
individuals consisting of 16 CCSDs patients and 16 controls from
the Shanghai and Shandong groups were randomly selected for
resequencing. All study protocols were reviewed and approved by
the ethics committee of School of Life Science, Fudan University,
and written consents were obtained from parents and/or patients
prior to commencing the study.
SNP identification and genotyping
Genomic DNA was isolated from venous blood using conven-
tional regents. The TYMS non-coding region from 22132 to
+447 bp (2579 bp, chr18: 645519–648098, NC_000018.8, GI:
51511735) and the fragment containing the whole 39UTR (742 bp,
chr18: 662863–663605, NC_000018.8, GI: 51511735) were
amplified by PCR from 32 unrelated individuals randomly selected
from both the Shanghai and Shandong groups for variant screening
using sequencing. Direct dye terminator sequencing of PCR
products was performed using the ABI Prism BigDye system
according to the manufacturer’s instructions (ABI, Foster City, CA,
USA). Selected SNPs were genotyped using SNAPshot analysis
(ABI, Foster City, CA, USA). Selected insertion/deletion sites were
genotyped using multi-PCR amplification. Sequencing and geno-
typing samples were processed on an ABI 3730 automated
sequencer and analyzed using SeqMan and Peakscan, respectively.
All DNA sequences of primer pairs were listed in Table S1.
Statistical analysis
Differences in demographic features, allelic or genotypic
frequencies between cases and controls were compared using the
x
2 test. The Hardy-Weinberg equilibrium was also tested by a x
2
test in the controls. To evaluate the associations between
genotypes and CCSDs risk, the odds ratios (ORs) and 95%
confidence intervals (CIs) were calculated by unconditional logistic
regression analysis with adjustment for age and sex.
The estimation of the haplotype frequency and the analysis of
associations between different haplotypes and CCSDs risk were
performed by the SNPStats web tool (http://bioinfo.iconcologia.
net/snpstats/start.htm) with adjustment for age and sex [21].
Results
By resequencing the 32 randomly chosen samples in the non-
coding region of TYMS, 19 polymorphisms were identified,
including 15 SNPs and 4 insertion/deletion polymorphisms.
Among the 19 polymorphisms, 10 SNPs and 3 insertion/deletion
polymorphisms were found in dbSNP of the NCBI database and 5
SNPs and 1 insertion/deletion polymorphism were novel.
According to the criteria for common variants, we chose 9 SNP
and 2 insertion/deletion polymorphisms with MAF.0.1 for
further exploration in both cohorts, which were rs58808873,
rs9967368, rs56697663, rs2853741, rs2606241, rs9952504,
rs34743033, rs73366471, rs699517, rs2790 and rs34489327.
We genotyped all 11 polymorphisms in 270 cases versus the 552
controls in the Shanghai group and 259 cases versus the 324
controls in the Shandong group. All genotype frequencies were in
accordance with the Hardy-Weinberg equilibrium among control
subjects (P.0.05). The allelic and genotypic frequencies of the 11
polymorphisms are listed in Table 2 and Table S2. The minor
allele frequency (MAF) for each polymorphism in our case/control
subjects was consistent with published data of Han Chinese
Table 1. Demographic characteristics in CCSDs cases and
controls.
Variable Cases Controls P value*
No. % No. %
Shanghai Group N=270 N=552
Age, years (mean6SEM) 4.4660.43 4.3960.15 0.87
Gender 0.81
Male 160 59.3 332 60.1
Female 110 40.7 220 39.9
Shandong Group N=259 N=324
Age, years (mean6SEM) 7.9360.32 8.0760.10 0.68
Gender 0.96
Male 118 45.6 147 45.3
Female 141 54.4 177 54.6
Combined Group N=529 N=876
Age, years (mean6SEM) 6.1660.28 5.7560.12 0.17
Gender 0.44
Male 278 52.6 479 54.7
Female 251 47.4 397 45.3
*All comparisons by 2-side x2 test. Date shown in the table is means (6SEM).
doi:10.1371/journal.pone.0031644.t001
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that the genotypic distribution of all studied polymorphisms were
not significantly different between the CCSDs patients and control
subjects in both two case/control groups and the combined
dataset. A stratified analysis was also performed in VSD subgroup,
as shown in Table S3, we did not observe any associations between
studied polymorphisms and VSD. These results indicate that these
polymorphisms are not significantly associated with the occurrence
of congenital cardiac septal defects, including the two most
extensively reported insertion/deletion sites, rs34743033 and
rs34489327.
In the haplotypic analysis, we reconstructed the haplotype for
the whole gene based on studied polymorphisms to assess risks for
both the case-control groups and the combined group. As shown
in Table S4, there were two haplotypes increasing the risk of
CCSDs in the Shanghai group, but the frequencies of these
haplotypes were very low (Frequency of No. 11 haplo-
type=0.0163, P=0.04; Frequency of No. 14 haplotype=0.0136,
P=0.04). Moreover, these two haplotypes didn’t exist in
Shandong group where we hadn’t observed any other associations
between haplotypes and CCSDs risk (Table S5). To exclude the
possibility that the different haplotype analysis results from two
cohorts were due to the hidden population stratification, we tested
the shared high frequency haplotypes (Frequency.5%) distribu-
tions in control groups and all sample set of both cohorts,
respectively. The results showed that there was no population
substructure existed (Table S6). Therefore, we performed the
haplotype analysis In the combined group and found that there
were no haplotypes significantly associated with risks for CCSDs
(Table 3). These two positive haplotypes in Shanghai group might
attribute to the bias from limited sample size and low frequency.
Further study will be warranted with the enlarged sample size for a
conclusive results.
Discussion
Epidemiological evidence indicates that periconceptional ad-
ministration of folic acid leads to a reduction of the risk of
delivering newborns with congenital heart disease, especially in
cardiac septal defects and conotruncal cardiac defects, which
makes exploring the association between genetic variants in folate-
related genes and the risk of congenital heart disease an attractive
pursuit. TYMS is the exclusive gene for de novo synthesis of dTMP,
which is essential for DNA synthesis. Many studies were
performed to investigate the relation between mutations/poly-
morphisms of coding region of TYMS and various diseases, such as
colorectal cancer, lymphoma and acute lymphocytic leukemia.
Polymorphisms in the noncoding region, however, have been
largely ignored except for two extensively studied insertion/
deletion polymorphisms, and limited studies have been conducted
Table 2. The allelic and genotype frequency of the TYMS polymorphisms in CCSD patients and controls.
SNP ID
Chromosome
Position
Base
change Location Group MAF
Genotype
P
$
HWE
P
&
Case Control Database*
rs58808873 645876 C.T Promoter region Shanghai 0.174 0.175 0.200 0.65 0.37
Shandong 0.192 0.164 0.28 0.31
rs9967368 646021 C.G Promoter region Shanghai 0.432 0.442 0.427 0.80 0.55
Shandong 0.462 0.442 0.70 0.18
rs56697663 647278 2.C Promoter region Shanghai 0.391 0.393 N.A.
# 0.91 0.72
Shandong 0.421 0.408 0.81 0.25
rs2853741 647353 T.C Promoter region Shanghai 0.462 0.499 0.475 0.31 0.27
Shandong 0.491 0.485 0.92 0.12
rs2606241 647444 A.C Promoter region Shanghai 0.371 0.347 0.425 0.27 1
Shandong 0.408 0.431 0.50 0.11
rs9952504 647459 A.G Promoter region Shanghai 0.0760 0.0695 0.092 0.90 0.17
Shandong 0.106 0.0890 0.61 0.30
rs34743033 647675 I.D5 9UTR Shanghai 0.202 0.201 0.237 0.53 0.43
Shandong 0.195 0.204 0.89 0.49
rs73366471 648036 A.G Intron 1 Shanghai 0.0740 0.0660 N.A.
# 0.80 0.29
Shandong 0.0545 0.0555 0.96 0.25
rs699517 663017 T.C3 9UTR Shanghai 0.313 0.285 0.300 0.49 1
Shandong 0.301 0.345 0.28 0.39
rs2790 663087 A.G3 9UTR Shanghai 0.368 0.390 0.375 0.22 0.089
Shandong 0.423 0.389 0.17 0.91
rs34489327 663445 D.I3 9UTR Shanghai 0.311 0.316 0.302 0.71 0.17
Shandong 0.333 0.326 0.97 0.38
*MAF, minor allele frequency from HapMap database for CHB population.
$P value for difference in genotypes distributions between case and control subjects.
&P value for Hardy-Weinberg equilibrium test in the control subjects. Additional detailed genotype frequencies is present in Table S2.
#Not available in dbSNP database.
doi:10.1371/journal.pone.0031644.t002
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directly.
In the current study, we explored the relationship between
polymorphisms in the non-coding region (including promoter
region, 59UTR and 39UTR) of TYMS and congenital cardiac
septal defects, and 11 common polymorphisms were selected for
genotyping in the association study of two independent groups. As
a consequence, none of specific disease-related polymorphisms or
haplotypes have been found, which indicate that the polymorphic
TYMS’s non-coding region is not associated with the elevated
cardiac septal defects risk in the Han Chinese population. Other
studies performed in conotruncal cardiac defects obtained similar
results although different regulatory polymorphisms and ethnic
groups were used in association studies [9,15]. Taking into account
all the investigations above, no sufficient evidence has been
demonstrated for a significant association between TYMS
polymorphisms and congenital heart disease,which suggests that
the protection effects of folate administration for CCSDs may not
be directly influenced by the pyrimidine synthesis.
The folate-dependent TYMS shares the same substrate (5,10-
methylene tetrahydrofolate, methylene-5THF) with 5,10-methyle-
netetrahydrofolate reductase (MTHFR). Consequently, the avail-
able TYMS for folate is competitively affected by MTHFR. It was
previously described that because the recycle from methylene-
5THF to the folate pool is catalyzed mainly by MTHFR, the
controls of the plasma folate concentration were significantly
attributed to the MTHFR polymorphisms compared with TYMS
polymorphisms [16]. Here, our results support that the TYMS
polymorphisms do not perform as an independent genetic risk
factor for the elevated incidence of congenital cardiac septal
defects. Additionally, the pathway of folate metabolism is in charge
of de novo DNA precursor synthesis and methylation [22]. The
occurrence of CCSDs might be attributed more to the
methylation, considering DNA or protein methylation would play
a significant role in the embryo heart development. The negative
results derived from present study could be alternatively explained
by the central role TYMS played in DNA synthesis and repair. The
TYMS mutations leading to function or dosage mutation may
create a powerful selective effect by resulting in great detriments
on embryonic development, such as serious defects or even death.
However, the samples of CCSDs examined in this study,
characterized as a type of medium and mild congenital heart
disease, cannot tolerate severe functional mutations. This
hypothesis could be corroborated by the results of the exon’s
sequencing of TYMS in the same examined samples, where no case
of missense mutation has been found in the TYMS entire coding
region of 200 ventricular septal defect samples (data not shown).
Moreover, a potential limitation might also be imposed on the
presence of polymorphisms with severe regulatory malfunctions in
the non-coding region.
With respect to the characteristics of TYMS’s structure, no
canonical eukaryotic transcriptional signals such as the TATA
box, CAAT box and GC box are found in the 59 upstream region
of TYMS. Instead, three sequences consistent with GC boxes were
reported by Kaneda in intron-1 [23] and other regulatory
sequences were further identified within intron-1, which could
stimulate the TYMS gene expression in concert with the 59 non-
coding region [24]. Furthermore, many common polymorphic
sites were identified in the TYMS promoter and UTR region in the
current study, indicating a high tolerance for polymorphisms (one
SNP per 160 bp). Consequently, we postulate that the promoter
and UTR region may not be the core regulatory region for the
expression of TYMS gene, while intron-1 of TYMS might play a
more associative role in the regulation of gene expression [25]. In
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the regulation of TYMS mRNA level may attribute mostly to post-
transcriptional events in humans [26]. Thus, more attention
should be placed on intron-1 in the future research related to
TYMS expression and function.
In addition, our study is limited to the neonatal genotype and
lacks research for the maternal genotype. It is also possible that the
protective effect of periconceptional supplement of folic acid is
generated by the adjustment of the maternal metabolic defect,
which is associated closely with maternal genotype instead of the
neonatal genotype. The information of maternal dietary folate
intake during pregnancy is also not available in this study. It was
noted that the strongest associations between polymorphisms of
folate-related genes and congenital heart defects might be observed
only when environmental factors are taken into consideration [11–
13]. We can’t exclude the possibility that the effect of TYMS
polymorphisms might be influenced by the interacted maternal
folate status. Additional studies will be required to determine the
levels of maternal serum folate concentration, which would help to
figure out valuable polymorphisms in TYMS.
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